Research Portal

Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

Research output: Contribution to journal › Article › peer-review

Standard Standard

Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. / Sivaprasad, S.; Prevost, A.T.; Vasconcelos , J. C et al.
In: The Lancet, Vol. 389, No. 10085, 03.06.2017, p. 2193-2203.

Research output: Contribution to journal › Article › peer-review

HarvardHarvard

Sivaprasad, S, Prevost, AT, Vasconcelos , JC, A, R, Murphy, C, Kelly, J, J, B, Edwards, RT, Hopkins, D & Hykin, P 2017, 'Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial', The Lancet, vol. 389, no. 10085, pp. 2193-2203. https://doi.org/10.1016/S0140-6736(17)31193-5

APA

Sivaprasad, S., Prevost, A. T., Vasconcelos , J. C., A, R., Murphy, C., Kelly, J., J, B., Edwards, R. T., Hopkins, D., & Hykin, P. (2017). Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. The Lancet, 389(10085), 2193-2203. https://doi.org/10.1016/S0140-6736(17)31193-5

CBE

Sivaprasad S, Prevost AT, Vasconcelos JC, A R, Murphy C, Kelly J, J B, Edwards RT, Hopkins D, Hykin P. 2017. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. The Lancet. 389(10085):2193-2203. https://doi.org/10.1016/S0140-6736(17)31193-5

MLA

Sivaprasad, S. et al. "Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial". The Lancet. 2017, 389(10085). 2193-2203. https://doi.org/10.1016/S0140-6736(17)31193-5

VancouverVancouver

Sivaprasad S, Prevost AT, Vasconcelos JC, A R, Murphy C, Kelly J et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. The Lancet. 2017 Jun 3;389(10085):2193-2203. Epub 2017 May 7. doi: 10.1016/S0140-6736(17)31193-5

Author

Sivaprasad, S. ; Prevost, A.T. ; Vasconcelos , J. C et al. / Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. In: The Lancet. 2017 ; Vol. 389, No. 10085. pp. 2193-2203.

RIS

TY - JOUR

T1 - Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial

AU - Sivaprasad, S.

AU - Prevost, A.T.

AU - Vasconcelos , J. C

AU - A, Riddell

AU - Murphy, C

AU - Kelly, J

AU - J, Bainbridge

AU - Edwards, Rhiannon Tudor

AU - Hopkins, David

AU - Hykin, Philip

N1 - The Efficacy and Mechanism Evaluation Programme, a Medical Research Council and National Institute for Health Research partnership.

PY - 2017/6/3

Y1 - 2017/6/3

U2 - 10.1016/S0140-6736(17)31193-5

DO - 10.1016/S0140-6736(17)31193-5

M3 - Article

VL - 389

SP - 2193

EP - 2203

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10085

ER -